From today's $18.5 billion merger and acquisition, look at the opportunities that the new crown outbreak has brought to the healthcare industry.

Today, Teleadoc Health, a company dedicated to telemedicin, announced an agreement with Livongo, which innovates chronic care by remotely collecting health information.
Willadoc will merge with Livongo to unlock the full potential of telemediccare, combining their expertise in telemediced and chronic disease care.
the deal is expected to be worth $18.5 billion.
the world's new crown epidemic has caused a huge impact on many industries around the world, tourism, retail, aviation, etc. have been greatly affected.
the healthcare industry, the new crown outbreak has also hampered many clinical trials and affected the development of innovative therapies.
However, "dangerous" often after the "machine", one of the major impact of the new crown outbreak is the rise of telemedicine, because of fear of being infected with the virus, many patients from the way to go to the clinic to online consultation.
Andoc and Livongo are undoubtedly the two companies that have seized the "opportunity" under the outbreak.
, a new technology-based medical experience, Teladoc, launched in 2015 and has built a telemediced technology platform that allows patients to conduct remote consultations via video with doctors who join the technology platform.
U.S., more than 70 million people have access to doctors through Teleadoc's technology platform.
company is also expanding its business worldwide.
livongo, which went public in an IPO last year, aims to help chronically ill patients manage their condition by combining instruments such as intelligent blood glucose detectors and smart scales that can transmit patient health data to the cloud.
chronic diseases include diabetes, high blood pressure, weight management, and behavioral health.
the impact of the new crown outbreak and the dramatic increase in patient demand for telemedicine and disease control, both companies' businesses have expanded.
The two companies have been among the top IPOs in MedTech, according to a recent first-half 2020 investment and financing report from a prominent Silicon Valley bank, reflecting investors' concerns about telemedicination and health management.
source: Resources: The two companies say the merger will provide more patients with a technology-based, all-round, individual, one-stop medical care experience.
While telemedicine has grown rapidly as a result of the new crown outbreak, industry sources believe that even if the new crown outbreak is contained, the potential of telemedicine and smart devices in the outbreak will continue to contribute to the further development of this area.
this is a major opportunity for the health care industry brought by the new crown outbreak.
New Crown Outbreak: "Accelerators" and "teststones" of innovative technology According to the World Health Organization (WHO), more than 18.5 million people worldwide are currently infected with the new crown virus, and nearly 700,000 people have lost their lives as a result.
extent of the new crown epidemic and the severity of patients' conditions represent a huge unsealed medical need and a potential "accelerator" and "testing block" for innovative technologies to address this need.
example, Moderna, which is working on mRNA therapy, developed the fastest-growing mRNA therapy to phase 2 clinical before the outbreak.
However, using new technology for the mRNA vaccine after the outbreak, the company launched Phase I clinical trials 63 days after the release of the new crown virus genome sequence, and the mRNA new crown vaccine is now being tested in Phase 3 clinical trials and may be tested by the end of this year.
results of this trial will not only reveal the efficacy and safety of this candidate vaccine to prevent new coronary virus infection, but are also considered by the industry to be a test of mRNA vaccine/therapy technology.
raDx process schematics (Photo source: Credit, NIH) In the field of diagnostic testing, the new crown outbreak has also led to the expansion of innovative diagnostic technologies.
, the National Institutes of Health (NIH) announced that its Rapid Acceleration of Diagnostics (RADx) program has been layered to screen seven biotech companies for further development of COVID-19 tests from more than 650 applications, expanding production and pushing them to regulatory approval, with a potential for a massive increase in detection capabilities for new coronary viruses by the end of the summer and early fall.
these companies' testing technologies include portable PCR instruments, microflow chips, next-generation sequencing systems, pathogen detection systems based on CRISPR gene editing, and more.
we may not be unfamiliar with the names of these technologies, the demand for new crown outbreaks provides an unprecedented platform for rapid and large-scale testing of their effectiveness.
testing technology that has been tested by this "testing stone" is expected to enable us to better respond to future pandemics.
according to Silicon Valley Bank analysts' forecasts, venture capital institutions' investment in the biopharmaceutical industry is expected to reach an all-time high by 2020, and the level of fund-raising by venture capital institutions focused on biopharmaceuticals will reach an all-time high.
in the first half of this year, more than a third of companies that received funding in diagnostic testing/research and development tools used their technology to help overcome new crown outbreaks in every way.
from these data, it can be seen that innovations in the field of health care are still favored by capital markets under the epidemic.
"Sinking boat side thousands of sails over the disease tree before the first thousand wood spring", although the outbreak of the new crown outbreak destroyed some of the old order in the field of health care, but also delayed the conduct of many clinical trials, but it also brought new opportunities.
We look forward to the promotion and application of new treatments and health management models, with the help of capital, and the rapid growth of innovative biotechnology companies that ultimately lead to more and better solutions to improve patient health."
: Teladoc Health and Livongo Merge to Create New Standard in Global Healthcare Delivery, Access and Experience. Retrieved August 5, 2020, from Telemedicine is booming - but many people still face huge barriers to virtual care. Retrieved August 5, 2020, from Teladoc-Livongo, setting a new standard for the delivery, access and experience of healthcare. Retrieved August 5, 2020, from Healthcare Investments and Exits. Retrieved August 5, 2020, from ▽ attention to the Public No.